# A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

> **NCT01942083** · PHASE1 · TERMINATED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** OPB-111077

## Key facts

- **NCT ID:** NCT01942083
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05-29
- **Primary completion:** 2016-06-01
- **Final completion:** 2016-07-11
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01942083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01942083, "A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01942083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*